Get the Stockscreener App
167.50
1.58%
2.61
Jazz Pharmaceuticals Plc stock is traded at $167.50, with a volume of 606.10K.
It is up +1.58% in the last 24 hours and up +22.52% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$164.89
Open:
$164.89
24h Volume:
606.10K
Relative Volume:
0.61
Market Cap:
$10.18B
Revenue:
$4.09B
Net Income/Loss:
$-404.84M
P/E Ratio:
-24.83
EPS:
-6.7469
Net Cash Flow:
$1.24B
1W Performance:
-1.30%
1M Performance:
+22.52%
6M Performance:
+51.87%
1Y Performance:
+35.52%
1-Day Range:
$163.77
$168.30
1-Week Range:
$161.00
$170.87
52-Week Range:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
167.50 | 10.02B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
AQR Arbitrage LLC Sells 9,118 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Mary Elizabeth Henderson Sells 2,238 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Holdings Lowered by California Public Employees Retirement System - MarketBeat
Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing - marketscreener.com
Guggenheim Capital LLC Sells 11,619 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Piper Sandler Raises Price Target for Jazz Pharmaceuticals (JAZZ) to $219 | JAZZ Stock News - GuruFocus
Piper Sandler raises Jazz Pharmaceuticals stock price target to $219 on positive trial results - Investing.com Nigeria
Carr Patricia, SVP at Jazz Pharma, sells $797k in JAZZ stock - Investing.com India
Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals (Nasdaq: JAZZ) shares Phase 4 DUET Xywav data in narcolepsy, IH - Stock Titan
Kennedy Capital Management LLC Buys Shares of 10,367 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking After Shares Rocket 29% - 富途牛牛
Schroder Investment Management Group Acquires 8,444 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook - Yahoo Finance
Jazz Pharmaceuticals to present new Epidiolex data at epilepsy meeting By Investing.com - Investing.com Nigeria
Affinity Asset Advisors LLC Makes New $2.65 Million Investment in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Do New Epidiolex Real‑World Data Reframe Jazz Pharmaceuticals' (JAZZ) Neurology Growth Ambitions? - simplywall.st
VP Carr Files To Sell 4,660 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting - marketscreener.com
Jazz Pharmaceuticals to present new Epidiolex data at epilepsy meeting - Investing.com
Jazz Pharmaceuticals (Nasdaq: JAZZ) unveils EpiCom and real-world Epidiolex findings at AES 2025 - Stock Titan
Saturn V Capital Management LP Buys New Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher - Yahoo Finance
Dir O'Keefe Surrenders 603 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Will Jazz Pharmaceuticals plc stock pay special dividendsEarnings Beat & High Conviction Buy Zone Picks - Newser
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Systematic Financial Management LP - MarketBeat
Is Jazz Pharmaceuticals plc (J7Z) stock attractive for growth fundsEarnings Summary Report & Real-Time Buy Signal Alerts - Newser
Why hedge funds are buying Jazz Pharmaceuticals plc stock2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - Newser
What MACD trends signal for Jazz Pharmaceuticals plc (J7Z) stockPortfolio Profit Report & Expert Verified Movement Alerts - Newser
How Jazz Pharmaceuticals plc (J7Z) stock performs in easing cyclesShort Setup & Weekly Market Pulse Updates - Newser
Mackenzie Financial Corp Raises Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Prudential Financial Inc. - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Distillate Capital Partners LLC - MarketBeat
Will Jazz Pharmaceuticals plc (J7Z) stock benefit from infrastructure billQuarterly Performance Summary & Fast Moving Market Watchlists - Newser
Will Jazz Pharmaceuticals plc (J7Z) stock outperform benchmarksQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Why Jazz Pharmaceuticals plc (J7Z) stock appeals to dividend investorsPrice Action & AI Driven Stock Movement Reports - Newser
Does Jazz Pharmaceutical's Acquisition of Gentium S.p.A. Signal Investment Upside? - AOL.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $13,780,275.00 in Stock - MarketBeat
Jazz to present pivotal phase 3 results for Ziihera in GEA at ASCO GI - Investing.com Canada
Jazz Pharmaceuticals (Nasdaq: JAZZ) to present Ziihera Phase 3 GEA data at ASCO GI - Stock Titan
Looking Into Jazz Pharmaceuticals PLC's Recent Short Interest - Benzinga
Capital Fund Management S.A. Takes $4.27 Million Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Loomis Sayles & Co. L P Trims Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Is Jazz Pharmaceuticals plc stock attractive for retirement portfoliosJuly 2025 Recap & Reliable Entry Point Trade Alerts - Newser
Why Jazz Pharmaceuticals plc (J7Z) stock remains stableJuly 2025 Momentum & Fast Gain Swing Alerts - Newser
Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium - PR Newswire
Dir O'Keefe Files To Sell 1,249 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz Pharmaceuticals Director Bruce C. Cozadd Sells 77,500 Shares - TradingView
Chmn Cozadd Sells 77,500 ($13.8M) Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):